ProCE Banner Events

Thrombotic Risk in Patients With Polycythemia Vera | Identify When to Intervene With Jakafi® (ruxolitinib)

Key Learning Objectives

  • Encourage participants to clinically assess how they would manage a real-world patient with PV
  • Recognize the correlation between elevated blood counts and thrombotic risk by applying data from the CYTO-PV Study
  • Evaluate treatment options in PV utilizing the RESPONSE and MAJIC-PV trials that investigated Jakafi® (ruxolitinib) vs best available therapy
  • Understand when to intervene and potential outcomes for patients with PV

This event has expired. No longer available for credits.

Time and location

Wednesday, July 17, 2024

12:15 PM - 12:45 PM Eastern Time (ET)

Virtual

Faculty
Edward Pearson, MD

Medical Oncologist
Texas Oncology
Dallas, Texas

Sponsored By

ProCE Banner

Additional Information

Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. The Company is advancing a diversified portfolio of clinical candidates across Oncology and Inflammation & Autoimmunity.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For more information, visit Incyte.com and follow @Incyte [twitter.com]

Therapeutic Area: Polycythemia Vera Oncology